Discordant FIB-4 and liver stiffness in metabolic dysfunction-associated steatotic liver disease as related to histology and liver-related events in a global cohort: Editorial on “Histological severity and hepatic outcomes in patients with metabolic dysfunction-associated steatotic liver disease and discrepant FIB-4 and liver stiffness measurement”
Abstract
HCC, hepatocellular carcinoma; VCTE, vibration controlled transient elastography Metabolic dysfunction-associated steatotic liver disease (MASLD) affects over 30% of individuals worldwide, and with the continued rise in both obesity and type 2 diabetes, is projected to affect more than half of the global population within the next two decades.(1-2)Given this steep rise in MASLD prevalence, it is important to improve both detection and management in an impactful yet cost effective manner.Recent data demonstrate that, histologically, fibrosis stage is the strongest determinant of mortality and liver related events (LRE) in MASLD.(3)While the gold standard for detecting fibrosis remains liver biopsy, it is often impractical as it is costly, invasive, and carries risk of procedural complications.Thus, noninvasive liver
Fields of Study & Subjects
Liver Disease Diagnosis and Treatment
Genetic and Kidney Cyst Diseases
Pediatric Hepatobiliary Diseases and Treatments
Publication details
- Journal / source
- Clinical and Molecular Hepatology
- Publisher
- The Korean Association for the Study of the Liver
- Volume
- 32
- Issue
- 3
- Pages
- 1409–1412
- Publication date
- 9 January 2026
- Language
- EN